Oxular Ltd Revenue and Competitors

Oxford,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Oxular Ltd's estimated annual revenue is currently $4.3M per year.(i)
  • Oxular Ltd's estimated revenue per employee is $155,000

Employee Data

  • Oxular Ltd has 28 Employees.(i)
  • Oxular Ltd grew their employee count by -18% last year.

Oxular Ltd's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP - QualityReveal Email/Phone
3
Senior Director Clinical OperationsReveal Email/Phone
4
Associate Director Procurement and Supply ChainReveal Email/Phone
5
Director Drug DevelopmentReveal Email/Phone
6
Chief Product OfficerReveal Email/Phone
7
Chief Scientific OfficerReveal Email/Phone
8
Finance DirectorReveal Email/Phone
9
Director Information ManagementReveal Email/Phone
10
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Oxular Ltd?

“One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular's sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular's drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular's product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$4.3M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.9M2833%N/A
#2
$4.5M29-6%N/A
#3
$5.9M29-6%N/A
#4
$2.9M29-9%N/A
#5
$2.9M29-3%N/A